The General Hospital Corporation

General Electric Company

Yongqing Li

Hasan B Alam

Kevin George Harding

Guiju Song

Joseph Benjamin Ross

Ralph Gerald Isaacs

Jianming Zheng

Ming Jia

The technology described herein is directed to the treatment of sepsis and/or septic shock by, e.g. administering an agent that can reduce the level of circulating citrullated histones.

Treatment of sepsis and septic shock

Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).

Biomarkers of hemorrhagic shock

A computer-implemented method, system, and computer program code are provided for characterizing an edge break, e.g., part features and/or geometric discontinuities that could give rise to edge sharpness, as may be encountered in a chamfer, bevel, fillet and other part features. The methodology enables to accurately and consistently determine in a manufacturing setting, for example, any applicable geometric parameter for characterizing the edge break.

Computer-implemented techniques and system for characterizing geometric parameters of an edge break in a machined part

Growing community of inventors

Ann Arbor, MI, United States of America

Yongqing Li